- The UK authorisation was granted on 10 August 2026.
- Daily tablets still require prescribing and monitoring.
- A licence does not automatically establish NHS access.
What the MHRA authorised
The Medicines and Healthcare products Regulatory Agency authorised orforglipron, branded Foundayo, on 10 August 2026. Its weight-management indication covers adults with an initial BMI of at least 30, or at least 27 and below 30 with a weight-related condition, alongside a reduced-calorie diet and increased physical activity. It also has a type 2 diabetes indication.
This places Foundayo among licensed UK treatments, rather than experimental medicines awaiting their first authorisation. It remains prescription only. Meeting a BMI threshold is one part of assessment; it does not establish that a particular medicine is suitable for every person.
An oral medicine still needs a treatment plan
The approved product information describes once-daily use without food or water restrictions. That may be relevant to someone comparing daily routines, but convenience should be considered alongside medical history, other medicines, tolerability and the support available during treatment.
The same product information includes warnings about pancreatitis, severe gastrointestinal symptoms and dehydration, and about low blood sugar when used with insulin or certain other diabetes medicines. Nausea, vomiting and diarrhoea occurred particularly during dose escalation. An oral formulation does not remove the need to discuss side effects and follow-up with a prescriber.
Trial reports and the marketed tablets may describe different dose amounts because the clinical programme used a capsule formulation. Readers should use the instructions for the actual prescribed product; research-dose numbers are not a basis for adjusting tablets.
Approval and NHS access are different decisions
MHRA authorisation assesses a medicine for specified uses. NHS funding involves additional decisions about clinical and cost effectiveness and local delivery. The August approval announcement explicitly distinguished authorisation from NHS availability.
This article confirms the authorisation, not an individual entitlement to NHS treatment or a live pharmacy supply position. For a practical decision, check current national guidance and the criteria used by the service providing care. A planned appraisal date alone cannot establish that funding has been recommended.
Sources & further reading
These links support the information above; they do not imply endorsement of this website.
Written for a UK audience by the Health Comparisons editorial team. This page is an information resource and has not been presented as a clinician’s personal recommendation. Discuss treatment decisions with your prescriber.
Read our editorial standards →